Agile Therapeutics Gets a Buy Rating from Noble Financial

By Carrie Williams

Noble Financial analyst Mark Jordan reiterated a Buy rating on Agile Therapeutics (NASDAQ: AGRX) on June 12. The company’s shares closed yesterday at $3.68.

According to, Jordan is a 1-star analyst with an average return of -1.6% and a 47.7% success rate. Jordan covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Adamas Pharmaceuticals, and Corbus Pharmaceuticals.

Agile Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $9.

Based on Agile Therapeutics’ latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $0 and GAAP net loss of $7.52 million. In comparison, last year the company earned revenue of $0 and had a GAAP net loss of $7.32 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Agile Therapeutics, Inc. engages in the development and commercialization of new prescription contraceptive products. Its product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company was founded on December 22, 1997 and is headquartered in Princeton, NJ.